[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU26596A - REKOMBINANTNI PROTEINI GOJAZNOSTI (Ob) - Google Patents

REKOMBINANTNI PROTEINI GOJAZNOSTI (Ob)

Info

Publication number
YU26596A
YU26596A YU26596A YU26596A YU26596A YU 26596 A YU26596 A YU 26596A YU 26596 A YU26596 A YU 26596A YU 26596 A YU26596 A YU 26596A YU 26596 A YU26596 A YU 26596A
Authority
YU
Yugoslavia
Prior art keywords
recombinant
obese
proteins
recombinant obese
obesity
Prior art date
Application number
YU26596A
Other languages
English (en)
Inventor
Arthur Campfield
Rane Devos
Yves Guisez
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of YU26596A publication Critical patent/YU26596A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Proteini koji moduliraju telesnu težinu životinja i ljudi radi lečenja, prevencije i kontrole gojaznosti i njoj srodnih bolesti i stanja, i rekombinantna ekspresija ovih biološki aktivnih proteina u prečišćenim i homogenim oblicima.
YU26596A 1995-05-05 1996-05-06 REKOMBINANTNI PROTEINI GOJAZNOSTI (Ob) YU26596A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43577795A 1995-05-05 1995-05-05
US48462995A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
YU26596A true YU26596A (sh) 1999-03-04

Family

ID=27030682

Family Applications (1)

Application Number Title Priority Date Filing Date
YU26596A YU26596A (sh) 1995-05-05 1996-05-06 REKOMBINANTNI PROTEINI GOJAZNOSTI (Ob)

Country Status (35)

Country Link
US (1) US6025325A (sh)
EP (1) EP0741187A2 (sh)
JP (1) JP3244627B2 (sh)
KR (1) KR100219970B1 (sh)
CN (1) CN1157290A (sh)
AR (1) AR003087A1 (sh)
AU (1) AU688210B2 (sh)
BG (1) BG62975B1 (sh)
BR (1) BR9602166A (sh)
CA (1) CA2175298A1 (sh)
CZ (1) CZ129796A3 (sh)
DE (1) DE741187T1 (sh)
ES (1) ES2093593T1 (sh)
GR (1) GR960300075T1 (sh)
HR (1) HRP960213A2 (sh)
HU (1) HU220093B (sh)
IL (1) IL118059A0 (sh)
IS (1) IS4343A (sh)
MA (1) MA23856A1 (sh)
MY (1) MY132189A (sh)
NO (1) NO961796L (sh)
NZ (1) NZ286466A (sh)
OA (1) OA10362A (sh)
PE (1) PE50897A1 (sh)
PL (1) PL186568B1 (sh)
RO (1) RO117177B1 (sh)
RU (1) RU96109211A (sh)
SG (1) SG49337A1 (sh)
SK (1) SK56996A3 (sh)
SV (1) SV1996000030A (sh)
TN (1) TNSN96066A1 (sh)
TR (1) TR199600357A2 (sh)
TW (1) TW464655B (sh)
UY (1) UY24219A1 (sh)
YU (1) YU26596A (sh)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
ATE267255T1 (de) * 1995-12-27 2004-06-15 Genentech Inc Ob proteinderivate mit verlängerter halbwertzeit
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
EP0877627A1 (en) * 1996-01-25 1998-11-18 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US7067472B1 (en) * 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US20030036629A1 (en) * 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
EP1290170A2 (en) 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
US20040018959A1 (en) * 2002-05-02 2004-01-29 Randall S. Hickle System and methods of lipid removal from the body
DE602004005477T2 (de) 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
PT2626368T (pt) * 2004-07-19 2017-03-10 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
NZ585135A (en) * 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
AU2009248914A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
EP2352510A4 (en) * 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
US20140018290A1 (en) 2011-01-26 2014-01-16 Novo Nordisk A/S Leptin derivatives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199337A (en) * 1978-10-06 1980-04-22 International Telephone And Telegraph Corporation Method of fabricating high strength optical preforms
US4666836A (en) * 1981-01-02 1987-05-19 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU3329895A (en) * 1994-08-17 1996-03-07 Rockefeller University, The Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
AU4766196A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
CA2223433C (en) * 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
ATE267255T1 (de) * 1995-12-27 2004-06-15 Genentech Inc Ob proteinderivate mit verlängerter halbwertzeit

Also Published As

Publication number Publication date
RO117177B1 (ro) 2001-11-30
MA23856A1 (fr) 1996-12-31
IS4343A (is) 1996-12-09
PL186568B1 (pl) 2004-01-30
NZ286466A (en) 1998-03-25
NO961796L (no) 1996-11-06
MY132189A (en) 2007-09-28
CZ129796A3 (en) 1997-01-15
HU9601120D0 (en) 1996-06-28
AU688210B2 (en) 1998-03-05
BR9602166A (pt) 1998-01-13
US6025325A (en) 2000-02-15
HUP9601120A2 (en) 1996-11-28
TNSN96066A1 (fr) 2005-03-15
EP0741187A2 (en) 1996-11-06
SK56996A3 (en) 1997-04-09
GR960300075T1 (en) 1996-12-31
BG100558A (bg) 1997-03-31
AR003087A1 (es) 1998-07-08
TR199600357A2 (tr) 1996-11-21
DE741187T1 (de) 1997-04-30
HU220093B (hu) 2001-10-28
IL118059A0 (en) 1996-08-04
RU96109211A (ru) 1998-10-27
PE50897A1 (es) 1997-12-19
HRP960213A2 (en) 1997-10-31
PL314051A1 (en) 1996-11-12
SV1996000030A (es) 1999-01-14
HUP9601120A3 (en) 1999-07-28
JPH093098A (ja) 1997-01-07
KR100219970B1 (ko) 1999-10-01
CN1157290A (zh) 1997-08-20
KR960041194A (ko) 1996-12-19
OA10362A (fr) 2001-11-15
SG49337A1 (en) 1998-05-18
TW464655B (en) 2001-11-21
CA2175298A1 (en) 1996-11-06
ES2093593T1 (es) 1997-01-01
NO961796D0 (no) 1996-05-03
EP0741187A3 (sh) 1996-12-11
BG62975B1 (bg) 2000-12-29
UY24219A1 (es) 2001-03-16
MX9601655A (es) 1997-07-31
AU5197896A (en) 1996-11-14
JP3244627B2 (ja) 2002-01-07

Similar Documents

Publication Publication Date Title
YU26596A (sh) REKOMBINANTNI PROTEINI GOJAZNOSTI (Ob)
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
DE69533991D1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
ATE362485T1 (de) Alloferone - immunomodulierende peptide
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
NO976094L (no) Nye peptider avledet av humant varmesjokkprotein 60 for behandling av diabetes, fremgangsmåte og sett
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
DK0821969T3 (da) Medicinsk sammensætning omfattende TCF-II
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
IT240104Y1 (it) Dispositivo per il trattamento del corpo umano.
ECSP961740A (es) Proteinas obesas (ob) recombinantes ram 4105/175
DE58902777D1 (de) Herrichtung und verwendung eines physiologisch aktiven polypeptids zur aids-therapie.
FR2708202B1 (fr) Implant biocompatible pour l'expression chez l'homme ou chez l'animal de substances déterminées.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
TH44140A (th) " รีคอมบิเนนท์ โอเบส (โอบี) โปรทีน "
IT224936Z2 (it) Presidio chirurgico radiotrasparente per il trattamento di patologie e traumi ortopedici.
ES1009573U (es) Protesis externa y ajustable para el tratamiento traumatologico de extremidades inferiores.
IT1275604B1 (it) Dispositivo per la riduzione di stenosi di organi del corpo umano